Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

February 28, 2010

Conditions
Breast Cancer
Interventions
DRUG

Myocet

Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles

DRUG

Taxotere

Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles

DRUG

Herceptin

Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles

Trial Locations (16)

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

20012

Onkologikoa, Donostia / San Sebastian

23007

Complejo Hospitalario de Jaén, Jaén

27004

Hospital Universitario Lucus Augusti, Lugo

29010

Hospital Clínico Universitario Virgen de la Victoria, Málaga

46009

Instituto Valenciano de Oncología, Valencia

46026

Hospital Universitario La Fe, Valencia

46600

Hospital de la Ribera, Alzira

50009

Hospital Universitario Miguel Servet, Zaragoza

03804

Hospital Universitario Virgen de los Lirios, Alcoy

08916

Hospital Universitario Germans Trias i Pujol, Badalona

08243

Althaia-Xarxa Assistencial de Manresa, Manresa

08208

Corporació Sanitaria Parc Taulí, Sabadell

08227

Consorci Sanitari de Terrassa, Terrassa

06080

Hospital Infanta Cristina, Badajoz

08036

Hospital Clinic i Provincial, Barcelona

Sponsors

Collaborators (3)

All Listed Sponsors
collaborator

Cephalon

INDUSTRY

collaborator

Sanofi

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Spanish Breast Cancer Research Group

OTHER

NCT00129896 - Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | Biotech Hunter | Biotech Hunter